Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) are effective in treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but only 20% of patients achieve durable responses. This study evaluated circulating tumor DNA (ctDNA) as a real-time biomarker for monitoring treatment response in HNSCC. The SHIZUKU-HN study prospectively collected and analyzed serial plasma samples (n = 27) from HNSCC patients undergoing ICIs, using Guardant360 to assess ctDNA variant allele frequency (VAF) and genetic mutations. Tumor volumes were quantified using 3D reconstruction of CT scans, and data from Japan’s C-CAT database (n = 2255) provided insights into ctDNA testing in HNSCC. C-CAT data showed that ctDNA testing was underutilized, performed in only 7% of head and neck cancer cases. In SHIZUKU-HN, mean VAF significantly correlated with tumor volume (Spearman’s ρ = 0.70, p = 0.001), often preceding radiographic progression. BRAF and APC mutations disappeared in partial responders, while GNAS mutations varied. EGFR and PIK3CA amplifications, detectable via ctDNA but missed in tissue biopsies, indicated emerging resistance mechanisms. The SHIZUKU-HN study demonstrates the potential of ctDNA as a dynamic biomarker in HNSCC, offering early insights into treatment efficacy and informing personalized ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For KRAS-mutant cancers such as CRC, PDAC, and potentially head and neck cancers [80], postoperative ctDNA detection may identify patients at high risk of recurrence and guide adjuvant therapeutic intensification.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Tumor response was assessed using RECIST 1.1 criteria [34], with efficacy classified as complete response (CR), partial response (PR), stable disease (SD, lasting > 6 months), or progressive disease (PD).”
InfluentialInvestigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,767 · cited 1×
“Statistical analyses were performed using the EZR (Easy R) software package version 1.54 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [41].”
InfluentialNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · cited 1×
“However, only about 20% of patients achieve a durable clinical response to ICIs, underscoring the urgent need to identify which patients are most likely to benefit from these therapies [1,2].”
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336 · cited 1×
“However, only about 20% of patients achieve a durable clinical response to ICIs, underscoring the urgent need to identify which patients are most likely to benefit from these therapies [1,2].”
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 1×
“…tumor DNA (ctDNA) from blood samples, has emerged as a promising non-invasive approach that allows real-time monitoring of tumor dynamics [6,7]. ctDNA reflects cancer-specific genetic alterations, providing a snapshot of the tumor’s genomic landscape that may change rapidly during treatment [8].”
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“NGS analysis was conducted using the Foundation One ® Companion Diagnostic (F1CDx; Foundation Medicine, Inc., Cambridge, MA, USA) test [40].”
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874 · cited 1×
“This finding aligns with previous research in lung cancer [15,16], where mean VAF has been validated as a reliable marker of tumor burden and dynamics.”
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“The incidence of immunotherapy pseudoprogression in head and neck cancer is reported to be less than 2% [33], but it is indistinguishable from true tumor progression on imaging evaluation alone.”
Landis, C. A., Masters, S. B., Spada, A., Pace, A. M., Bourne, H. R., & Vallar, L. (1989) · Nature · doi:10.1038/340692a0 · Cited by 1,441 · cited 1×
“These mutations are associated with excessive proliferation and tumor development [24,25].”
The molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395 · cited 1×
“Predictive biomarkers like programmed death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) have shown inconsistent predictive value [3–5], highlighting the limitations of current methods in guiding ICI therapy.”
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., Abida, W., Juluru, K., De Bruijn, I., Hou, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0652-7 · Cited by 769 · cited 2×
“…associated with clonal hematopoiesis of indeterminate potential (CHIP)—were common, re fl ecting the potential in fl uence of aging-related phenomena on ctDNA results [13,14]. was 65 days (range: 28–273 days), with radiographic evaluations conducted within 0–1.6 months of each ctDNA collection.”
InfluentialHodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698 · cited 1×
“BRAF mutations, especially those that activate the MAPK pathway [20,21], can increase tumor immunogenicity and enhance T-cell infiltration, potentially sensitizing tumors to ICIs [22].”
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1×
“Guardant360 sequences 74 cancer-associated genes to identify somatic alterations. cfDNA was extracted from plasma, enriched for targeted regions, and sequenced using the Illumina platform with hg19 as the reference genome [35–37].”
Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 435 · cited 1×
“Guardant360 sequences 74 cancer-associated genes to identify somatic alterations. cfDNA was extracted from plasma, enriched for targeted regions, and sequenced using the Illumina platform with hg19 as the reference genome [35–37].”
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 375 · cited 1×
“EGFR amplification likely contributed to aggressive tumor growth, while PIK3CA amplification, through activation of the PI3K/AKT pathway, may have facilitated immune evasion and treatment resistance [27,28].”
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373 · cited 1×
“The detected genomic alterations included single nucleotide variants (SNV), gene amplifications, fusions, short insertions/deletions (up to 70 base pairs), and splice site-disrupting events [38,39].”
Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0047 · Cited by 348 · cited 1×
“The detected genomic alterations included single nucleotide variants (SNV), gene amplifications, fusions, short insertions/deletions (up to 70 base pairs), and splice site-disrupting events [38,39].”
Raja, R., Kuziora, M., Brohawn, P. Z., Higgs, B. W., Gupta, A., Dennis, P. A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0386 · Cited by 239 · cited 1×
“The ctDNA dynamics during systemic treatment may be prognostic for clinical outcomes, even for treatments not associated with specific actionable genomic alterations, such as ICI [9] or broad-spectrum small molecule inhibitors [10].”
Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00520-1 · Cited by 223 · cited 1×
“%) between ctDNA and tissue samples observed in our study is notably lower than the typically reported rates of 50–80% in other solid tumors such as lung and colorectal cancers [29,30], where spatial and temporal heterogeneity limits the overlap between plasma and tissue genomic profiles.”
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
Kohno, T., Kato, M., Kohsaka, S., Sudo, T., Tamai, I., Shiraishi, Y., Okuma, Y., Ogasawara, D., Suzuki, T., Yoshida, T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0417 · Cited by 214 · cited 1×
“…the SHIZUKU-HN study aims to evaluate the potential of ctDNA as a real-time biomarker for monitoring treatment response in HNSCC patients undergoing ICI therapy, using data from Japan’s national genome database established by the Cancer Center for Advanced Cancer Genome Therapy (C-CAT) [11,12].”
Hankey, W., Frankel, W. L., & Groden, J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9725-6 · Cited by 207 · cited 1×
“The loss of APC mutations, which are known to disrupt tumor-suppressive pathways and promote aberrant Wnt signaling, suggests a reduction in immune evasion mechanisms [18,19].”
Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 192 · cited 1×
“For example, pseudoprogression occurs when immunotherapy activates an immune response to the tumor, resulting in necrosis, hemorrhage, and edema [31,32], an event that can complicate the clinician’s judgment during tumor evaluation.”
Clonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 111 · cited 2×
“…associated with clonal hematopoiesis of indeterminate potential (CHIP)—were common, re fl ecting the potential in fl uence of aging-related phenomena on ctDNA results [13,14]. was 65 days (range: 28–273 days), with radiographic evaluations conducted within 0–1.6 months of each ctDNA collection.”
InfluentialEffects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Bando, H., Nakamura, Y., Taniguchi, H., Shiozawa, M., Yasui, H., Esaki, T., Kagawa, Y., Denda, T., Satoh, T., Yamazaki, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00535 · Cited by 108 · cited 1×
“%) between ctDNA and tissue samples observed in our study is notably lower than the typically reported rates of 50–80% in other solid tumors such as lung and colorectal cancers [29,30], where spatial and temporal heterogeneity limits the overlap between plasma and tissue genomic profiles.”
Wilson, C. H., McIntyre, R. E., Arends, M. J., & Adams, D. J. (2010) · Oncogene · doi:10.1038/onc.2010.202 · Cited by 108 · cited 1×
“Wilson et al. demonstrated that the activating R201C mutation in GNAS promotes tumorigenesis in APC-inactivated mice via activation of the Wnt and ERK1/2 MAPK pathways [26].”
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103 · cited 1×
“BRAF mutations, especially those that activate the MAPK pathway [20,21], can increase tumor immunogenicity and enhance T-cell infiltration, potentially sensitizing tumors to ICIs [22].”
Self-citationMolecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
Thompson, J. C., Scholes, D. G., Carpenter, E. L., & Aggarwal, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02445-1 · Cited by 85 · cited 1×
“…tumor DNA (ctDNA) from blood samples, has emerged as a promising non-invasive approach that allows real-time monitoring of tumor dynamics [6,7]. ctDNA reflects cancer-specific genetic alterations, providing a snapshot of the tumor’s genomic landscape that may change rapidly during…”
Fujii, Y., Ono, A., Hayes, C. N., Aikata, H., Yamauchi, M., Uchikawa, S., Kodama, K., Teraoka, Y., Fujino, H., Nakahara, T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02016-3 · Cited by 52 · cited 1×
“The ctDNA dynamics during systemic treatment may be prognostic for clinical outcomes, even for treatments not associated with specific actionable genomic alterations, such as ICI [9] or broad-spectrum small molecule inhibitors [10].”
Mariot, V., Wu, J. Y., Aydin, C., Mantovani, G., Mahon, M. J., Linglart, A., & Bastepe, M. (2010) · Bone · doi:10.1016/j.bone.2010.09.032 · Cited by 51
Horie, S., Saito, Y., Kogure, Y., Mizuno, K., Ito, Y., Tabata, M., Kanai∥, T., Murakami, K., Koya, J., & Kataoka, K. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0902 · Cited by 48 · cited 1×
“…the SHIZUKU-HN study aims to evaluate the potential of ctDNA as a real-time biomarker for monitoring treatment response in HNSCC patients undergoing ICI therapy, using data from Japan’s national genome database established by the Cancer Center for Advanced Cancer Genome Therapy (C-CAT) [11,12].”
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
Rihawi, K., Giannarelli, D., Galetta, D., Delmonte, A., Giavarra, M., Turci, D., Garassino, M. C., Tiseo, M., Barbieri, F., Panni, S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.036 · Cited by 40 · cited 1×
“The disappearance of BRAF-mutated subclones might reflect adaptive resistance, where other resistant clones emerge, possibly involving pathways not captured in ctDNA [23].”
Edin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren‐Burström, A., Zingmark, C., Guelpen, B. R. V., Ljuslinder, I., Ling, A., & Palmqvist, R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02483-9 · Cited by 39 · cited 1×
“BRAF mutations, especially those that activate the MAPK pathway [20,21], can increase tumor immunogenicity and enhance T-cell infiltration, potentially sensitizing tumors to ICIs [22].”
Silvoniemi, A., Laine, J., Aro, K. L. S., Nissi, L., Bäck, L. J. J., Schildt, J., Hirvonen, J., Hagström, J., Irjala, H., Aaltonen, L., et al. (2023) · Cancers · doi:10.3390/cancers15153970 · Cited by 22 · cited 1×
“Previous research suggested a complementary role of metabolic tumor burden and VAF in the evaluation of HNSCC [17].”
Noji, R., Tohyama, K., Kugimoto, T., Kuroshima, T., Hirai, H., Tomioka, H., Michi, Y., Tasaki, A., Ohno, K., Ariizumi, Y., et al. (2022) · Cancers · doi:10.3390/cancers14143476 · Cited by 21 · cited 1×
“Predictive biomarkers like programmed death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) have shown inconsistent predictive value [3–5], highlighting the limitations of current methods in guiding ICI therapy.”
Self-citationCirculating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
Smith, J. T., Balar, A., Lakhani, D. A., Kluwe, C., Zhao, Z., Kopparapu, P., Almodovar, K., Muterspaugh, A., Yan, Y., York, S. J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100110 · Cited by 16 · cited 1×
“This finding aligns with previous research in lung cancer [15,16], where mean VAF has been validated as a reliable marker of tumor burden and dynamics.”
Matsudera, S., Kano, Y., Aoyagi, Y., Tohyama, K., Takahashi, K., Kumaki, Y., Mitsumura, T., Kimura, K., Onishi, I., Takemoto, A., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09856-5 · Cited by 13 · cited 1×
“…tumor DNA (ctDNA) from blood samples, has emerged as a promising non-invasive approach that allows real-time monitoring of tumor dynamics [6,7]. ctDNA reflects cancer-specific genetic alterations, providing a snapshot of the tumor’s genomic landscape that may change rapidly during…”
Self-citationTouchaei, A. Z., Vahidi, S., & Samadani, A. A. (2024) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2024.00015 · Cited by 6
Naito, T., Noji, R., Kugimoto, T., Kuroshima, T., Tomioka, H., Fujiwara, S., Suenaga, M., Harada, H., & Kano, Y. (2023) · Medicina · doi:10.3390/medicina59122111 · Cited by 4
Self-citation
Cited by
Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism
Yu, X., Gao, J., & Zhang, C. (2025) · Intensive Care Medicine Experimental · doi:10.1186/s40635-025-00728-w · Cited by 28
Advances in mitochondria–nucleus crosstalk in septic cardiomyopathy
Chen, W., Zhao, Z., Geng, Z., Zhang, H., & Fu, X. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10090-y · Cited by 16
Cancer drug response and resistance: molecular mechanisms and combating strategies
Cheng, X., Xu, M., Wei, J., & Cao, C. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02924-w · Cited by 20
Damodaran, S., Weeramange, C. E., Kenny, L., Vasani, S. S., Hughes, B. G. M., Breik, O., & Punyadeera, C. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10305-y · Cited by 6
Circulating tumour DNA in head and neck squamous-cell carcinomas: A literature review
Ventelou, L., Ginzac, A., Ferreira, M.-C., Canetti, L., Philippe, S., Pinard, C., Durando, X., & Bernadach, M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103070 · Cited by 6
Metadata
- Authors
- Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., Miura, M., Hamamoto, Y., Harada, H., & Kano, Y.
- Affiliations
- Institute of Science Tokyo (JP)
- Corresponding author
- Kano, Yoshihito
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-12-30
- Volume
- 26
- Issue
- 1
- Pages
- 235
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11719933
- OpenAlex
- W4405920634
- Cited by
- 11
- References
- 41
- Citations by year
- 2026: 6 · 2025: 5
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- JSPS KAKENHI (JP22K09680, JP21K10134, JP19K23909, JP22K21031)
- TMDU Research Grant for the Utilization of Big Data (JP22K09680, JP21K10134, JP19K23909, JP22K21031)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- circulating tumor DNA, head and neck squamous cell carcinoma, immune checkpoint inhibitors, liquid biopsy, variant allele frequency, treatment response monitoring, tumor volume, BRAF mutation, APC mutation, GNAS mutation, EGFR amplification, PIK3CA amplification, drug resistance
- MeSH terms
- Circulating Tumor DNA, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Female, Head and Neck Neoplasms, Humans, Immunotherapy, Male, Middle Aged, Mutation, Prospective Studies, Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.